不同治则中药复方对胆汁淤积性肝纤维化大鼠尿激酶型纤溶酶原激活剂的影响论文.docVIP

　　不同治则中药复方对胆汁淤积性肝纤维化大鼠尿激酶型纤溶酶原激活剂的影响论文 .freelula) on cholestasis-induced liver fibrosis rat’s uPA. Methods Bile duct ligation method ake the model of cholestasis-induced liver fibrosis. One ly divided into five group (model group, UDCA group, Erzhiedicine intervention group edicine by intragastric administration. Sham and model group chloride pled. General state of health, hepatic function (ALT, AST, ALP, TBil) and pathological histology of hepatic tissue easured. Results pared group, the level of ALT, AST, ALP, TBil and the degree of liver fibrosis in model group odel group, three Chinese herbal pound decreased serum level of ALP, ALT and AST (P＜0.01). Shixiaosan and hefang decreased serum level of TBil (P＜0.01). Hefang ple recipe on ALP and ALT. Three herbal pound released liver fibrosis to some extent (P＜0.01), and hefang ple recipe. UDCA decreased serum level of ALT and AST, but had no effect on liver fibrosis. pared odel group, uPA expression significantly increased in three Chinese herbal groups (P＜0.01), and hefang group iddle, Erzhioting blood circulation and removing blood stasis can inhibit the cholestasis-induced liver fibrosis. The mechanism a)；UV-2102C分光光度计(尤尼克公司)；OLYMPUS-ix71显微镜(日本OLYMPUS公司)；低温离心机为(eppendorf公司)；凝胶成像系统(上海四星生物技术有限公司)。 1.3 药物 二至丸由墨旱莲、女贞子各9 g组成；失笑散由五灵脂、蒲黄各6 g组成；合方由墨旱莲、女贞子各9 g,五灵脂、蒲黄各6 g组成。按公式计算给药。大鼠剂量＝人剂量×35(人转换因子)/6(大鼠转换因子)计算出人、鼠等效剂量,二至丸为1.75 g/(kg·d),失笑散为1.17 g/(kg·d),合方为2.92 g/(kg·d)。按传统工艺制备成水煎剂,分别减压浓缩至1.75、1.17、2.92 g/mL备用。优思弗(熊去氧胆酸,Dr.Falk Pahrma GmbH产品,注册证号：购自上海中医药大学龙华医院),同样方法计算出人、鼠等效剂量58.3 mg/(kg·d)。所有药物制备、质控由上海中医药大学附属龙华医院制剂中心完成。 2 实验方法 2.1 模型制备 参照文献1采用胆管结扎复制胆汁淤积性肝纤维化模型。术前禁食不禁水12 h,盐酸氯胺酮100 mg/kg肌肉注射麻醉,常规腹部皮肤消毒,沿腹正中线切开皮肤,暴露胆总管,于远近端结扎胆总管,中间离断,关腹；假手术组仅开腹暴露并游离胆总管不结扎,关腹。 2.2 分组及给药 SD大鼠70只,假手术组10只,其余60只造模。造模1周后,随机分为模型组(12只),优思弗、二至丸、失笑散及合方组各10只。各治疗组分别给予相应药物灌胃,每日1次,共计3周；假手术组与模型组以同体积生理盐水灌胃。4周末以盐酸氯胺酮腹腔注射麻醉(2 mL/kg),腹主动脉采血,处死全部实验动物,分离血清,-80 ℃保存备用。摘取肝脏称重后,于肝右叶切取1.0 cm×1.0 cm大小肝组织2块,4%中性甲醛溶液固定。 2.3 检测指标 2.3.1 一般情况 包括精神状态、活